红星资本局9月11日消息,靠着明星产品司美格鲁肽,短短三年间,丹麦制药巨头诺和诺德(NVO.N)成为全球资本市场的宠儿,一度登上欧洲市值最高公司的宝座。2025年一季度,司美格鲁肽销售额还击败了默沙东的K药,首次登顶全球“药王”宝座。9月10日,诺和诺德宣布启动全公司转型,旨在精简组织架构,提高决策速度,并将资源重新分配至公司在糖尿病和肥胖症领域的增长机会。该公司计划在全球裁员约9000人(公司...
Source Link红星资本局9月11日消息,靠着明星产品司美格鲁肽,短短三年间,丹麦制药巨头诺和诺德(NVO.N)成为全球资本市场的宠儿,一度登上欧洲市值最高公司的宝座。2025年一季度,司美格鲁肽销售额还击败了默沙东的K药,首次登顶全球“药王”宝座。9月10日,诺和诺德宣布启动全公司转型,旨在精简组织架构,提高决策速度,并将资源重新分配至公司在糖尿病和肥胖症领域的增长机会。该公司计划在全球裁员约9000人(公司...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.